Drug Profile

CBM H1

Alternative Names: CBM-H1

Latest Information Update: 02 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CellionBioMed
Class Vascular disorder therapies
Mechanism of Action Small-conductance calcium-activated potassium channel inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Dec 2022 CBM H1 is still in preclinical trial for Vascular disorders in South Korea (CellionBioMed pipeline, December 2022)
21 Jun 2022 Preclinical trials in Vascular disorders in South Korea (unspecified route), prior to June 2022 (CellionBioMed pipeline, June 2022)
21 Jun 2022 CellionBioMed plans a phase I trial for Vascular disorders, in 2023 (CellionBioMed pipeline, June 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com